The beta 3-Adrenergic Receptor Activates Mitogen-activated Protein Kinase in Adipocytes through a Gi-dependent Mechanism*

Kurt J. SoederDagger , Sheridan K. SneddenDagger , Wenhong Cao§, Gregory J. Della Rocca, Kiefer W. Daniel§, Louis M. Luttrellparallel , and Sheila CollinsDagger §**

From the Departments of § Psychiatry and Behavioral Sciences, Dagger  Pharmacology,  Biochemistry, and parallel  Medicine, Duke University Medical Center, Durham, North Carolina 27710

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Promiscuous coupling between G protein-coupled receptors and multiple species of heterotrimeric G proteins provides a potential mechanism for expanding the diversity of G protein-coupled receptor signaling. We have examined the mechanism and functional consequences of dual Gs/Gi protein coupling of the beta 3-adrenergic receptor (beta 3AR) in 3T3-F442A adipocytes. The beta 3AR selective agonist disodium (R,R)-5-[2[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL316,243) stimulated a dose-dependent increase in cAMP production in adipocyte plasma membrane preparations, and pretreatment of cells with pertussis toxin resulted in a further 2-fold increase in cAMP production by CL316,243. CL316,243 (5 µM) stimulated the incorporation of 8-azido-[32P]GTP into Galpha s (1.57 ± 0.12; n = 3) and Galpha i (1.68 ± 0.13; n = 4) in adipocyte plasma membranes, directly demonstrating that beta 3AR stimulation results in Gi-GTP exchange. The beta 3AR-stimulated increase in 8-azido-[32P]GTP labeling of Galpha i was equivalent to that obtained with the A1-adenosine receptor agonist N6-cyclopentyladenosine (1.56 ± 0.07; n = 4), whereas inclusion of unlabeled GTP (100 µM) eliminated all binding. Stimulation of the beta 3AR in 3T3-F442A adipocytes led to a 2-3-fold activation of mitogen-activated protein (MAP) kinase, as measured by extracellular signal-regulated kinase-1 and -2 (ERK1/2) phosphorylation. Pretreatment of cells with pertussis toxin (PTX) eliminated MAP kinase activation by beta 3AR, demonstrating that this response required receptor coupling to Gi. Expression of the human beta 3AR in HEK-293 cells reconstituted the PTX-sensitive stimulation of MAP kinase, demonstrating that this phenomenon is not exclusive to adipocytes or to the rodent beta 3AR. ERK1/2 activation by the beta 3AR was insensitive to the cAMP-dependent protein kinase inhibitor H-89 but was abolished by genistein and AG1478. These data indicate that constitutive beta 3AR coupling to Gi proteins serves both to restrain Gs-mediated activation of adenylyl cyclase and to initiate additional signal transduction pathways, including the ERK1/2 MAP kinase cascade.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Long before the discovery of the beta 3AR and its recognition as a unique, adipocyte-specific receptor controlling lipolysis and thermogenesis, Rodbell and colleagues (1) made the observation that there was an unusual, biphasic stimulation of cAMP production in adipocytes in response to the beta -adrenergic receptor agonist isoproterenol. Depending upon the concentration of GTP in the assay, isoproterenol could either stimulate or inhibit adenylyl cyclase activity in adipocyte plasma membranes. Murayama and Ui (2) showed that this inhibitory phase could be relieved by pretreatment of adipocytes with pertussis toxin (PTX).1 This curious observation lay fallow until studied later in greater detail by Bégin-Heick (3-5). However, it was not until the cloning and characterization of the beta 3AR gene and the development of selective beta 3AR agonists (6, 7) that it was postulated that this novel adipocyte-specific beta AR may be responsible for the biphasic adenylyl cyclase response in adipocytes (8). We have previously noted that despite the relatively high level of expression of the beta 3AR in adipocytes, the efficiency of coupling of the beta 3AR to stimulation of adenylyl cyclase is low (9). However, there has been no clear biochemical demonstration of physical coupling of the beta 3AR to Gi, other than comparative functional experiments in the presence or absence of PTX (10), nor has there been any indication of what additional second messenger pathway may be activated as a consequence of this putative coupling of beta 3AR to Gi.

Recently, many G protein-coupled receptors have been shown to mediate cellular growth or differentiation responses through the activation of MAP kinase cascades (11). Receptors signaling via PTX-sensitive Gi/o proteins, as well as PTX-insensitive Gq/11 proteins may activate the ERK1/2 MAP kinase cascade through a mechanism involving tyrosine protein phosphorylation and the activation of the low molecular weight G protein p21ras (12-14). Little is known about the potential role of beta ARs in the regulation of the MAP kinase pathway. Recently, we have found that in fibroblasts the beta 2AR mediates Ras-dependent ERK1/2 activation through its ability to couple to a PTX-sensitive Gi protein (15). beta 2AR coupling to Gi occurs as a result of PKA-dependent phosphorylation of the receptor, which effectively "switches" receptor coupling from Gs to Gi proteins. In contrast, beta 2AR-mediated ERK1/2 activation in S49 lymphoma cells is an entirely Gs-dependent process (16). In this system, PKA-mediated phosphorylation of the low molecular weight GTPase, Rap1, promotes Ras-independent ERK1/2 activation; this process was shown to be independent of beta 2AR interaction with Gi/o proteins. Therefore, it is not yet clear whether there is a common mechanism by which beta ARs activate MAP kinase.

Here, we demonstrate that stimulation of the beta 3AR in adipocytes induces the direct activation of both Gs and Gi. In these cells, Gi activation results in both the attenuation of beta 3AR-mediated stimulation of adenylyl cyclase and the activation of the ERK1/2 MAP kinase pathway. Unlike the beta 2AR signal in fibroblasts, beta 3AR activation of the ERK1/2 pathway is independent of cAMP and PKA. These data suggest that the promiscuous coupling of the beta 3AR in adipocytes permits the simultaneous transduction of two independent signaling pathways. This property of the beta 3AR may be responsible, in part, for the unique physiological effects of selective beta 3AR agonists in vivo, such as their potency for stimulating lipolysis (17, 18) and their ability to prevent or reverse obesity (6, 19-22).

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Chemicals-- CL316,243 was a gift from American Cyanamid Co. (Pearl River, NY). CGP20712A was a gift from CibaGeigy. Forskolin, bovine serum albumin (fraction V), insulin, (S)-(-)-propranolol, N6-2'-O-dibutyryladenosine 3':5'-cyclic monophosphate, and salbutamol were purchased from Sigma. EGF was obtained from Upstate Biotechnology (Lake Placid, NY). 8-Azido-[32P]GTP was purchased from Andotek Life Sciences (Irvine, CA). Pertussis toxin and genistein were purchased from Calbiochem. N6-Cyclopentyladenosine was obtained from RBI (Natick, MA). ICI 118551 was purchased from Cambridge Research Biochemicals (Wilmington, DE). Precast polyacrylamide gels were obtained from Novex (San Diego, CA).

Cell Culture and Transfections-- 3T3-F442A preadipocytes were maintained in Dulbecco's modified Eagle's medium supplemented with 10% calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin (Life Technologies, Inc.) at 37 °C in a humidified 5% CO2 atmosphere. Upon reaching 90% confluence, the cells were stimulated to differentiate into adipocytes by culturing in a differentiation media composed of Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 5 µg/ml insulin (23). HEK-293 cells were grown in six-well dishes and transfected with 1.2 µg of pBCbeta 3 or pBCbeta 2 DNA (24) by calcium phosphate co-precipitation (25). Ten h later, cells were washed in 1 mM EGTA in phosphate-buffered saline and incubated in growth medium for 24 h. The cells were then serum-starved for 24 h and treated with PTX (100 ng/ml), propranolol (10 µM), SR59230A (25 µM), CL316,243 (10 µM), or isoproterenol (100 µM), and MAP kinase assays were performed as described below. Cells that were pretreated with PTX were incubated with the toxin for 16-20 h at a concentration of 100 ng/ml.

Adenylyl Cyclase Assays-- Plasma membranes were prepared from 3T3-F442A adipocytes or Sprague-Dawley epididymal white adipose tissue as follows. For cultured cells, the monolayers were gently rinsed with ice-cold phosphate-buffered saline. All subsequent steps were performed at 4 °C. Lysis buffer (5 mM Tris/2 mM EDTA, pH 7.2, containing 10 µg/ml soybean trypsin inhibitor, 10 µg/ml benzamidine, 2 µg/ml aprotinin, and 0.1 mM phenylmethylsulfonyl fluoride) was added, and the cells were released from the dish with a rubber policeman. Following gentle disruption with a glass/Teflon homogenizer, nuclei were removed by centrifuging for 5 min at 800 × g. The supernatant was collected and centrifuged at 40,000 × g for 20 min. The pellet was resuspended in fresh lysis buffer with a Teflon pestle, centrifuged again, and then resuspended in a small volume of lysis buffer. For rat adipocytes obtained from epididymal adipose tissue, the same procedure was followed except that first the tissue was finely minced, and adipocytes were isolated by incubating the tissue pieces with collagenase (Worthington) (26). Adenylyl cyclase activity in plasma membranes was measured as described previously (9). Control incubations in the absence or presence of isobutylmethylxanthine (0.25 mM) found no evidence of particulate cyclic nucleotide phosphodiesterase activity in these plasma membranes. In some experiments, cAMP production was measured in intact 3T3-F442A adipocytes. For these whole cell assays, growth media was replaced with serum-free medium 3 h prior to stimulation. The serum-free medium consisted of Dulbecco's modified Eagle's medium supplemented with 1 g/liter fraction V bovine serum albumin, 10 mM HEPES, pH 7.4, 100 units/ml penicillin, and 100 µg/ml streptomycin. Then cells were incubated with the indicated concentrations of beta -agonist in fresh serum-free medium for 10 min at 37 °C in the presence of 0.25 mM isobutylmethylxanthine. Reactions were stopped by the addition of ice-cold 5% trichloroacetic acid, and particulate material was removed by centrifugation. The cAMP concentrations from both assay methods were determined by radioimmunoassay using a polyclonal antiserum to iodinated cAMP (27). Protein concentrations were determined by the method of Bradford (28).

Western Blotting and Photolabeling of Heterotrimeric G Proteins-- Western blotting was performed with antibodies specific for individual Galpha subunits. Adipocyte membranes (30 µg of protein) were solubilized in SDS-polyacrylamide gel electrophoresis sample buffer and resolved on 4-20% Novex gradient gels (San Diego, CA). A recombinant G protein standard mix containing Galpha i1, Galpha i2, Galpha i3, and Galpha o was included as a positive control (gift of Dr. Pat Casey). The proteins were then transferred to nitrocellulose membranes. The membranes were incubated for 16 h at 4 °C with rabbit anti-Galpha i1+2, anti-Galpha i3, or anti-Galpha s, 1:1000 dilution, followed by alkaline phosphatase-conjugated goat anti-rabbit antisera (1:10,000 dilution, Amersham Pharmacia Biotech) as secondary antibody. Immunoreactive bands were visualized by Storm PhosphorImager (Molecular Dynamics).

Synthesis and purification of the 8-azido-[32P]GTP was performed as described (29, 30) with minor modifications (31). For some experiments, 8-azido-[32P]GTP was purchased from Andotek Life Sciences. The photoaffinity labeling procedure of Offermanns (32) was followed with modifications (31). For labeling of the Galpha i subunits, adipocyte membranes (50 µg of protein) were incubated with 8-azido-[32P]GTP (0.5 µCi) for 10 min at 30 °C in a volume of 60 µl containing 50 mM HEPES (pH 7.6), 1 mM EDTA, 50 mM NaCl, 500 µM MgCl2, 50 µM GDP, 100 µM ATP, and 1 µg/ml adenosine deaminase in the presence or absence of the adenosine A1 receptor agonist N6-cyclopentyladenosine or the beta 3AR-selective agonist CL316,243. Labeling of the Galpha s subunit was performed as above at a free Mg2+ concentration of 2-5 mM. The binding reactions were stopped by placing tubes on ice, and all subsequent steps were performed at 4 °C. The membranes were collected by centrifugation for 10 min at 14,000 × g and resuspended in a buffer containing 50 mM HEPES (pH 7.6), 1 mM EDTA, 50 mM NaCl, 500 µM MgCl2, and 2 mM dithiothreitol. Following irradiation of the samples with a UV lamp (4 watts, 254 nm) at a distance of 3 cm for 5 min, the samples were collected by centrifugation as before and solubilized in Laemmli sample buffer. Proteins labeled with 8-azido-[32P]GTP were resolved by SDS-polyacrylamide gel electrophoresis using a 10% polyacrylamide gel and visualized by a Storm PhosphorImager (Molecular Dynamics).

MAP Kinase Assays-- Activation of MAP kinase was determined by measuring the phosphorylation state of ERK 1 and ERK 2 (33). For this assay, 3T3-F442A cells were grown and differentiated in six-well culture plates and serum-starved for 24 h prior to stimulation with beta -adrenergic agonists or growth factors. The serum-free medium consisted of Dulbecco's modified Eagle's medium supplemented with 1 g/liter fraction V bovine serum albumin, 10 mM HEPES, pH 7.4, 100 units/ml penicillin, and 100 µg/ml streptomycin. Five min after the addition of beta -agonists or growth factors, the medium was removed, and the cells were solubilized by the direct addition of Laemmli sample buffer (34). These cell lysates were sonicated for 5 s, and aliquots (30 µg protein/lane) were resolved by SDS-polyacrylamide gel electrophoresis. ERK1/2 phosphorylation was detected by protein immunoblotting using a 1:3000 dilution of rabbit polyclonal phospho-MAP kinase-specific antisera (NEBiolabs) with a 1:10,000 dilution of alkaline phosphatase-conjugated goat anti-rabbit antisera (Amersham Pharmacia Biotech) as secondary antibody. Quantitation of ERK1/2 phosphorylation was performed using a Storm PhosphorImager (Molecular Dynamics). After quantitation of ERK1/2 phosphorylation, nitrocellulose membranes were stripped of immunoglobulin and reprobed using rabbit polyclonal anti-ERK 2 IgG (Upstate Biotechnology, Inc.) to confirm equal amounts of ERK 2 protein.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Stimulation of 3T3-F442A adipocyte plasma membranes with the selective beta 3AR agonist CL316,243 resulted in a 3-4-fold increase in adenylyl cyclase activity Fig. 1A). Membranes prepared from cells pretreated with PTX exhibited a more robust increase in cAMP production, which was at least 2-fold above that observed in membranes from naive cells. Whereas basal levels of cAMP generation were elevated following PTX treatment, the effect of PTX on the -fold activation of adenylyl cyclase by forskolin was minimal (Fig. 1B). We obtained similar results from Chinese hamster ovary cells, which heterologously express the mouse beta 3AR (data not shown) (35). These results suggest that the beta 3AR is constitutively coupled to both Gs and Gi, because inhibition of Gi function leads to increased tonic production of cAMP.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 1.   beta 3AR agonist stimulation of cAMP production in 3T3-F442A adipocytes. A, dose-response curve for agonist stimulation of cAMP production in response to CL316,243. Membranes of untreated or PTX-pretreated adipocytes were prepared and incubated with increasing agonist concentrations. Cyclic AMP production was measured by radioimmunoassay using polyclonal antisera to iodinated cAMP. The data shown are representative of two dose-response experiments. B, basal (Bas) and forskolin (FSK)-stimulated cAMP production in untreated and PTX-pretreated membranes. The data shown are the average of four experiments.

Rat white adipocytes have been shown to contain the two splice variants of Galpha s and the three isoforms of Galpha i (alpha i1, alpha i2, alpha i3) (5, 36). As shown in Fig. 2, 3T3-F442A adipocytes express the same repertoire of G proteins as found in rat white adipocytes: two splice variants of Galpha s, Galpha i3, and Galpha i1/Galpha i2. Others have previously shown that adipocytes do not contain the PTX-sensitive Galpha o protein (36-39). To determine whether the PTX effects on cAMP production resulted from constitutive coupling of the beta 3AR to both Gs and Gi, the photolabile GTP analog 8-azido-[32P]GTP was used to measure beta 3AR agonist-dependent GTP loading of Galpha s and Galpha i. This method has been used by several investigators to demonstrate physical coupling between G protein-coupled receptors and individual G protein alpha  subunits, based upon several well defined criteria for receptor-G protein interaction (40-42). Because the binding of GTP analogs to Galpha subunits is highly dependent upon free magnesium concentrations (31), we conducted our experiments in adipocyte plasma membranes under separate conditions favorable for 8-azido-[32P]GTP labeling of each Galpha family. Because the beta 3AR is coupled to Galpha s and activation of adenylyl cyclase, Fig. 3A shows that under high magnesium conditions, which favor receptor-stimulated GTP loading of Galpha s, CL316,243 could stimulate specific 8-azido-[32P]GTP labeling of Galpha s (1.57 ± 0.12; n = 3; p < 0.001). Under low magnesium conditions, which are optimal for determining receptor-stimulated GTP loading to Galpha i, there was a similar 1.68 ± 0.13-fold increase (n = 4; p < 0.001) in specific 8-azido-[32P]GT G protein labeling of the 40-42-kDa Galpha i species (Fig. 3B). We obtained similar data from 3T3-F442A membranes (not shown). Fig. 3B also shows that the ability of CL316,243 to stimulate Gi-GTP exchange in adipocyte membranes was equivalent to that obtained with the A1-adenosine receptor agonist N6-cyclopentyladenosine (1.56 ± 0.07; n = 4; p < 0.001). N6-Cyclopentyladenosine served as a positive control because the A1-adenosine receptor is expressed in both primary adipocytes (43, 44) and differentiated 3T3-F442A adipocytes (45) and couples to all three Galpha i species (46, 47).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2.   G protein alpha  subunit determination. Plasma membranes from 3T3-F442A adipocytes and rat epididymal white adipose tissue (EWAT) were resolved by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The complement of G protein alpha  subunits present was assessed by Western blotting as described under "Materials and Methods." Std, G protein standard.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Labeling of Galpha subunits by 8-azido-[32P]GTP in adipocyte membranes in response to beta 3AR stimulation. A, 8-azido-[32P]GTP labeling of Galpha s in response to no stimulation (NS) or labeling with CL316,243 (CL) (5 µM) in rat white adipocyte membranes. B, 8-azido-[32P]GTP labeling of the 40-42-kDa Galpha i/o species in response to no stimulation, N6-cyclopentyladenosine (CPA) (50 nM), and CL316,243 (5 µM) in rat white adipocyte membranes. The effect of excess GTP is also shown. Data shown are the average of three experiments (for Galpha s) or four experiments (for Galpha i) and are expressed as -fold change over nonstimulated control. *, significantly different from unstimulated control, p < 0.001.

A number of Gi-coupled receptors have been shown capable of activating MAP kinase (11). Recently, Daaka and colleagues (15) reported that the beta 2AR could couple to both Galpha s and Galpha i, with consequent activation of MAP kinase. We therefore determined whether one of the functional consequences of the coupling of the beta 3AR to Galpha i in 3T3-F442A adipocytes was the stimulation of MAP kinase. Intact 3T3-F442A adipocytes treated with CL316,243 (5 µM) exhibited approximately a 2.5-fold stimulation of ERK1/2 phosphorylation (Fig. 4). Activation of the endogenous beta 2AR in 3T3-F442A adipocytes with the beta 2AR-selective agonist salbutamol also yielded a similar 2-fold stimulation of ERK1/2 phosphorylation. Both beta AR responses were less robust than that observed following activation of endogenous receptors for EGF, consistent with previous findings (13). Also shown in Fig. 4, pretreatment of 3T3-F442A adipocytes with PTX completely blocked ERK1/2 phosphorylation in response to either beta 2AR or beta 3AR stimulation, but it did not affect stimulation by EGF. The addition of propranolol (0.1 µM) eliminated ERK1/2 phosphorylation in response to salbutamol but had no effect on the activation of MAP kinase induced by CL316,243 (not shown), consistent with a CL-mediated effect exclusively through the beta 3AR (7).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of beta -agonists and PTX on ERK1/2 phosphorylation in 3T3-F442A adipocytes. Quantitation of ERK1/2 phosphorylation subsequent to agonist stimulation was determined by Western blotting with phosphospecific anti-ERK1/2 rabbit antisera. Quantitation was performed using a Storm PhosphorImager (Molecular Dynamics). Data shown are the average of four experiments and are expressed as the -fold change over nonstimulated control for salbutamol (1 µM), CL316,243 (5 µM), and EGF (10 ng/ml). Pretreatment with PTX was as detailed under "Materials and Methods." *, significantly different from unstimulated control by one-way analysis of variance, p < 0.001.

The relative sensitivity of the beta 3AR to activate MAP kinase versus cAMP accumulation in adipocytes was assessed by treating intact cells with increasing concentrations of CL316,243 (Fig. 5). Because the MAP kinase assays involve the stimulation of intact cells, we included cAMP dose-response data also from intact cells. The EC50 for cAMP production in these experiments was 12 nM, whereas parallel measurements of MAP kinase activation (EC50 = 280 nM) indicated that the PTX-sensitive coupling of the beta 3AR to MAP kinase activation is less potent under these conditions. Nevertheless, the dose-response curves for both measurements yielded a unit slope, indicative of the high selectivity of CL316,243 for the beta 3AR (7, 48). Note that the EC50 for cAMP production in these whole cell experiments is significantly less than that found in plasma membranes (Fig. 1). However, it is generally recognized that dose-response curves as well as ligand binding data from intact cells are shifted "to the left," when compared with data obtained using isolated membrane preparations (49, 50). These comparative studies shown in Fig. 5 suggest that cAMP production is the favored pathway in response to activation of the beta 3AR in adipocytes. It must be remembered, however, that the catalytic activity of the subsequent kinases and their juxtaposition to substrate targets will ultimately determine the relative importance of these two pathways. Future studies will address these issues.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5.   Comparative dose-dependent stimulation of cAMP production () and MAP kinase activation (black-square) in 3T3-F442A adipocytes. Differentiated 3T3-F442A adipocytes were incubated with increasing concentrations of CL316,243 and processed for measurement of cAMP or ERK1/2 phosphorylation as detailed under "Materials and Methods." The data were analyzed by nonlinear curve-fitting routines (GraphPad Prism) (9). The results shown are from two independent experiments.

To determine whether the dual Gs/Gi coupling of the beta 3AR and activation of MAP kinase was an adipocyte-specific event or a unique feature of the rodent beta 3AR, we attempted to reconstruct these effects by transiently transfecting the human beta 3AR into HEK-293 cells. As shown in Fig. 6A, transient transfection of the hbeta 3AR resulted in a low basal level of ERK1/2 phosphorylation (lane 2), and stimulation with the beta 3AR agonist increased ERK1/2 phosphorylation ~4-fold above basal level (lane 3), as compared with the 7-8-fold activation achieved by EGF (lane 7). There was no effect of the beta 3AR agonist on mock-transfected cells (lane 1). This activation of MAP kinase by the hbeta 3AR was completely blocked by the selective beta 3AR antagonist, SR59230A (lane 4) (51). In addition, the nonselective beta AR agonist isoproterenol at a concentration capable of activating the beta 3AR (100 µM), in the presence of propranolol, also led to an ~4-fold stimulation of ERK1/2 phosphorylation (lane 5). Finally, PTX completely eliminated MAP kinase activation (lane 6), as observed in 3T3-F442A adipocytes (Fig. 4). Together these data suggest that the dual coupling of the beta 3AR to Gs/Gi, along with its activation of MAP kinase, is a general property of this receptor.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 6.   HEK-293 cells transiently expressing the human beta 3AR activate MAP kinase. A, HEK-293 cells were transiently transfected with the hbeta 3AR as described under "Materials and Methods." Cells were treated as shown, and ERK1/2 phosphorylation was determined. B, HEK-293 cells transiently expressing human beta 3AR or human beta 2AR were pretreated with H-89 (20 µM), genistein (5 µM), or AG1478 (3 µM) for 40 min before agonist stimulation. The results shown represent one of three experiments. CL, CL316,243; ISO, isoproterenol.

Mechanistically, beta 2AR-mediated MAP kinase activation in fibroblasts requires sequential receptor coupling to Gs and Gi, because cAMP-dependent, PKA-mediated phosphorylation of the beta 2AR is a prerequisite for receptor-Gi coupling (15). To compare the role of cAMP and PKA in beta AR-mediated MAP kinase activation in adipocytes, we compared the effects of the PKA inhibitor H-89 on beta 2AR- and beta 3AR-stimulated MAP kinase activation. As shown in Fig. 6B, H-89 blocked beta 2AR-stimulated MAP kinase activation (lane 8), consistent with the results of Daaka et al. (15). In contrast, the beta 3AR signal was insensitive to H-89 (lane 3). Fig. 6B also shows that MAP kinase activation by the beta 3AR was sensitive to low micromolar concentrations of the tyrosine kinase inhibitor genistein (lane 4) and to the EGR receptor tyrphostin AG1478 (lane 5). These results indicate that, like other Galpha i-coupled receptors, the beta 3AR employs a tyrosine kinase receptor in its mechanism of recruiting MAP kinase (52, 53). In other experiments, treatment with dibutyryl cAMP enhanced beta 2AR-stimulated ERK1/2 phosphorylation by ~70%, consistent with the model of PKA-dependent beta 2AR-Gi coupling. However, stimulation of MAP kinase by the beta 3AR was unaffected by dibutyryl cAMP (data not shown). Together, these results indicate that MAP kinase activation via the beta 3AR, unlike the beta 2AR, is insensitive to modulation of the PKA pathway. Thus beta 3AR-mediated MAP kinase activation can be distinguished in several ways from the beta 2AR pathway. First, the beta 3AR is not a substrate for PKA (24). Second, the beta 3AR appears to be constitutively coupled to both Gs and Gi. Third, beta 3AR-stimulated activation of cAMP is not required for activation of the MAP kinase cascade in adipocytes. In contrast to the finding of PKA-dependent beta 2AR-mediated MAP kinase activation in S49 lymphoma cells (16), the beta 3AR pathway in adipocytes is completely PTX-sensitive.

One of the remarkable features of the beta 3AR is that treatment with beta 3AR-selective agonists in vivo can prevent or reverse obesity due to either congenital or diet-induced etiology (6, 19-22, 54). These agents are also efficacious over prolonged periods of administration (21), which is quite distinct from the rapid desensitization and down-regulation that is characteristic of chronic treatment with beta 1- and, particularly, beta 2AR-selective drugs (55, 56). These unique properties of the beta 3AR have been suggested to be related to the fact that beta 3AR is resistant to desensitization (57), because it is not a substrate for either PKA or the G protein-coupled receptor kinases (24). Instead, our finding that the beta 3AR is capable of activating both the PKA pathway and the MAP kinase cascade raises another possibility. The simultaneous recruitment of both signaling networks may result in a more potent stimulation of lipolysis and/or may promote the growth and differentiation of brown adipocytes, which is observed in all beta 3AR agonist-treated animals (20, 21, 58). It will now be important for us to test the consequence of impairing one or the other of these signal transduction pathways to determine their contribution to these beta 3AR-mediated responses.

    ACKNOWLEDGEMENTS

We thank Drs. Patrick Casey and Timothy Fields for advice and discussions on the synthesis and use of 8-azido-[32P]GTP and the gift of recombinant G protein standard mix. We thank Dr. Suzie Mumby for the antisera to Galpha i3, Dr. Tom Gettys for the cAMP antisera, Dr. Neil Freedman for the gift of pBCbeta 3 DNA, and Dr. Luciano Manara of SANOFI MIDI Research for the gift of SR59230A. We also acknowledge Dr. Robert J. Lefkowitz for helpful discussions during the development of this project.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants DK46793 and DK53092 (to S. C.) and DK02352 (to L. M. L.), National Institutes of Health Training Program Grants T32ES0731 (to K. J. S.) and T32GM07105 (to S. K. S.), and National Institutes of Health Medical Scientist Training Program Grant T32GM07171 (to G. J. D. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Duke University Medical Center, P. O. Box 3557, Durham, NC 27710. Tel.: 919-684-8991; Fax: 919-684-3071; E-mail: colli008{at}mc.duke.edu.

    ABBREVIATIONS

The abbreviations used are: PTX, pertussis toxin; beta AR, beta -adrenergic receptor; PKA, cAMP-dependent protein kinase; EGF, epidermal growth factor; MAP, mitogen-activated protein; ERK, extracellular signal-regulated kinase; CL316, 243, disodium (R,R)-5-[2[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate; SR59230A, 3-(2-ethylphenoxy)-1-[(1S)-1,2,3,4-tetrahydronapth-1-ylamino]-(2S)-2-propanol oxalate; AG1478, 4-(3-chloroanilino)-6,7-dimethoxyquinazoline; CGP20712A, 1-[2-((3-carbamoyl-4-hydroxy)phenoxy)ethylamino]-3-[4-O-methyl-4-trifluoromethyl-2-imidazoyl)phenoxy]-2-propanol methane sulfonate.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES
  1. Cooper, D., Schlegel, W., Lin, M., and Rodbell, M. (1979) J. Biol. Chem. 254, 8927-8931[Abstract]
  2. Murayama, T., and Ui, M. (1983) J. Biol. Chem. 258, 3319-3326[Abstract/Free Full Text]
  3. Bégin-Heick, N. (1985) J. Biol. Chem. 260, 6187-6193[Abstract/Free Full Text]
  4. Begin-Heick, N. (1987) 53, 1-8
  5. Begin-Heick, N. (1990) Biochem. J. 268, 83-89[Medline] [Order article via Infotrieve]
  6. Arch, J. R. S., Ainsworth, A. T., Cawthorne, M. A., Piercy, V., Sennitt, M. V., Thody, V. E., Wilson, C., and Wilson, S. (1984) Nature 309, 163-165[Medline] [Order article via Infotrieve]
  7. Bloom, J. D., Dutia, M. D., Johnson, B. D., Wissner, A., Burns, M. G., Largis, E. E., Dolan, J. A., and Claus, T. H. (1992) J. Med. Chem. 35, 3081-3084[Medline] [Order article via Infotrieve]
  8. Begin-Heick, N. (1995) J. Cell. Biochem. 58, 464-473[Medline] [Order article via Infotrieve]
  9. Collins, S., Daniel, K. W., Rohlfs, E. M., Ramkumar, V., Taylor, I. L., and Gettys, T. W. (1994) Mol. Endocrinol. 8, 518-527[Abstract]
  10. Chaudhry, A., MacKenzie, R. G., Georgic, L. M., and Granneman, J. G. (1994) Cell. Signal. 6, 457-465[CrossRef][Medline] [Order article via Infotrieve]
  11. Van Biesen, T., Luttrell, L. M., Hawes, B. E., and Lefkowitz, R. J. (1996) Endocr. Rev. 17, 698-714[Medline] [Order article via Infotrieve]
  12. Koch, W., Hawes, B., Allen, L., and Lefkowitz, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12706-12710[Abstract/Free Full Text]
  13. van Biesen, T., Hawes, B. E., Luttrell, D. K., Kreuger, K. M., Touhara, K., Porfiri, E., Sakaue, M., Luttrell, L. M., and Lefkowitz, R. J. (1995) Nature 376, 781-784[CrossRef][Medline] [Order article via Infotrieve]
  14. Crespo, P., Xu, N., Simonds, W. F., and Gutkind, J. S. (1994) Nature 369, 418-420[CrossRef][Medline] [Order article via Infotrieve]
  15. Daaka, Y., Luttrell, L. M., and Lefkowitz, R. J. (1997) Nature 390, 88-91[CrossRef][Medline] [Order article via Infotrieve]
  16. Wan, Y., and Huang, X.-Y. (1998) J. Biol. Chem. 273, 14533-14537[Abstract/Free Full Text]
  17. Hollenga, C., Brouwer, F., and Zaagsma, J. (1991) Eur. J. Pharmacol. 200, 325-330[Medline] [Order article via Infotrieve]
  18. Hollenga, C., Brouwer, F., and Zaagsma, J. (1991) Br. J. Pharmacol. 102, 577-580[Abstract]
  19. Largis, E. E., Burns, M. G., Muenkel, H. A., Dolan, J. A., and Claus, T. H. (1994) Drug Dev. Res. 32, 69-76
  20. Himms-Hagen, J., Cui, J., Danforth, E., Jr., Taatjes, D. J., Lang, S. S., Waters, B. L., and Claus, T. H. (1994) Am. J. Physiol. 266, R1371-R1382[Abstract/Free Full Text]
  21. Collins, S., Daniel, K. W., Petro, A. E., and Surwit, R. S. (1997) Endocrinology 138, 405-413[Abstract/Free Full Text]
  22. Sasaki, N., Uchida, E., Niiyama, M., Yoshida, T., and Saito, M. (1998) J. Vet. Med. Sci. 60, 465-469[CrossRef][Medline] [Order article via Infotrieve]
  23. Djian, P., Phillips, M., and Green, H. (1985) J. Cell. Physiol. 124, 554-556[Medline] [Order article via Infotrieve]
  24. Liggett, S., Freedman, N. J., Schwinn, D. A., and Lefkowitz, R. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3665-3669[Abstract]
  25. Oppermann, M., Freedman, N. J., Alexander, R. W., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 13266-13272[Abstract/Free Full Text]
  26. Rodbell, M. (1964) J. Biol. Chem. 239, 375-380[Free Full Text]
  27. Harper, J. F., and Brooker, G. (1975) J. Cyclic Nucleotide Res. 1, 207-218[Medline] [Order article via Infotrieve]
  28. Bradford, M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
  29. Pfeuffer, T. (1977) J. Biol. Chem. 252, 7224-7234[Medline] [Order article via Infotrieve]
  30. Schafer, R., Christian, A. L., and Schulz, I. (1988) Biochem. Biophys. Res. Commun. 155, 1051-1059[Medline] [Order article via Infotrieve]
  31. Fields, T. A., Linder, M. E., and Casey, P. J. (1994) Biochemistry 33, 6877-6883[Medline] [Order article via Infotrieve]
  32. Offermanns, S., Schultz, G., and Rosenthal, W. (1991) Methods Enzymol. 195, 286-300[Medline] [Order article via Infotrieve]
  33. Della Rocca, G. J., van Biesen, T., Daaka, Y., Luttrell, D. K., Luttrell, L. M., and Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 19125-19132[Abstract/Free Full Text]
  34. Laemmli, U. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  35. Nahmias, C., Blin, N., Elalouf, J.-M., Mattei, M. G., Strosberg, A. D., and Emorine, L. J. (1991) EMBO J. 10, 3721-3727[Abstract]
  36. Gettys, T. W., Ramkumar, V., Uhing, R. J., Seger, L., and Taylor, I. L. (1991) J. Biol. Chem. 266, 15949-15955[Abstract/Free Full Text]
  37. Chang, K., Pugh, W., Blanchard, S., McDermed, J., and Tam, J. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 4929-4933[Abstract]
  38. Rouot, B., Carrette, J., Lafontan, M., Lan Tran, P., Fehrentz, J., Bockaert, J., and Toutant, M. (1989) Biochem. J. 260, 307-310[Medline] [Order article via Infotrieve]
  39. Hinsch, K. D., Rosenthal, W., Spicher, K., Binder, T., Gausepohl, H., Frank, R., Schultz, G., and Joost, H. G. (1988) FEBS Lett. 238, 191-196[CrossRef][Medline] [Order article via Infotrieve]
  40. Wange, R. L., Smrcka, A. V., Sternweis, P. C., and Exton, J. H. (1991) J. Biol. Chem. 266, 11409-11412[Abstract/Free Full Text]
  41. Gettys, T. W., Fields, T. A., and Raymond, J. R. (1994) Biochemistry 33, 4283-4290[Medline] [Order article via Infotrieve]
  42. Herrlich, A., Kühn, B., Grosse, R., Schmid, A., Schultz, G., and Gudermann, T. (1996) J. Biol. Chem. 271, 16764-16772[Abstract/Free Full Text]
  43. Vannucci, S. J., Klim, M., Martin, L. F., and LaNoue, K. F. (1989) Am. J. Physiol. 257, E871-E878[Abstract/Free Full Text]
  44. Larrouy, D., Galitzky, J., and Lafontan, M. (1991) Eur. J. Pharmacol. 206, 139-147[CrossRef][Medline] [Order article via Infotrieve]
  45. Ravid, K., and Lowenstein, J. M. (1988) Biochem. J. 249, 377-381[Medline] [Order article via Infotrieve]
  46. Jockers, R., Linder, M. E., Hoheneger, M., Nanoff, C., Bertin, B., Strosberg, A. D., Marullo, S., and Freissmuth, M. (1994) J. Biol. Chem. 269, 32077-32084[Abstract/Free Full Text]
  47. Munshi, R., Pang, I.-H., Sternweis, P. C., and Linden, J. (1991) J. Biol. Chem. 266, 22285-22289[Abstract/Free Full Text]
  48. Rohlfs, E. M., Daniel, K. W., Premont, R. T., Kozak, L. P., and Collins, S. (1995) J. Biol. Chem. 270, 10723-10732[Abstract/Free Full Text]
  49. Pittman, R. N., and Molinoff, P. B. (1983) Mol. Pharmacol. 24, 398-408[Abstract]
  50. Clark, R. B. (1986) Adv. Cyclic Nucleotide Protein Phosphorylation Res. 20, 151-209[Medline] [Order article via Infotrieve]
  51. Manara, L., Badone, D., Baroni, M., Boccardi, G., Cecchi, R., Croci, T., Giudice, A., Guzzi, U., Landi, M., and Le Fur, G. (1996) Br. J. Pharmacol. 117, 435-442[Abstract]
  52. Gutkind, J. (1998) J. Biol. Chem. 273, 1839-1842[Free Full Text]
  53. Lefkowitz, R. J. (1998) J. Biol. Chem. 273, 18677-18680[Free Full Text]
  54. Yoshida, T., Sakane, N., Wakabayashi, Y., Umekawa, T., and Kondo, M. (1994) Life Sci. 54, 491-498[Medline] [Order article via Infotrieve]
  55. Hausdorff, W., Caron, M., and Lefkowitz, R. (1990) FASEB J. 4, 2881-2889[Abstract]
  56. Premont, R., Inglese, J., and Lefkowitz, R. (1995) FASEB J. 9, 175-182[Abstract/Free Full Text]
  57. Nantel, F., Bonin, H., Emorine, L. J., Ziberfarb, V., Strosberg, A. D., Bouvier, M., and Marullo, S. (1993) Mol. Pharmacol. 43, 548-555[Abstract]
  58. Champigny, O., Ricquier, D., Blondel, O., Mayers, R. M., Briscoe, M. G., and Holloway, B. R. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10774-10777[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.